Trial Profile
Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Amyloidosis
- Focus Diagnostic use
- Acronyms AMYLCAR
- 24 Aug 2020 Status changed from recruiting to discontinued.
- 19 Aug 2019 Planned End Date changed from 1 Jan 2018 to 1 Dec 2019.
- 19 Aug 2019 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2019.